Brookdale Announces Fourth Quarter and Full Year 20...(and 2006 were as follows (in thousands):...),Health

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Type

Recurring $6,303 $9,181 $27,404 $26,272

Reimbursements (742) (681) (2,356) (2,754)

Net recurring 5,561 8,500 25,048 23,518

Corporate(1) 2,471 - 13,907 4,579

EBITDA-enhancing(2) 12,156 10,836 57,435 19,905

Development(3) 23,869 9,002 59,610 17,557

Other(4) 11,200 - 11,200 -

Net Total Capital Expenditures $55,257 $28,338 $167,200 $65,559

(1) Corporate primarily includes capital expenditures for information

technology systems and equipment.

(2) EBITDA-enhancing capital expenditures generally represent unusual or

non-recurring capital items and/or major renovations.

(3) Development capital expenditures primarily relate to the facility

expansion and de novo development program.

(4) Represents the impact of converting to accrual based reporting for

capital expenditures.

Our debt amortization for the three months and twelve months ended December 31, 2007 and 2006 was as follows (in thousands):

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Type

Scheduled Debt Amortization $403 $482 $1,866 $1,111

Lease Financing Debt Amortization -

FMV Purchase Option
'/>"/>